Sound View Wealth Advisors Group LLC boosted its position in Danaher Co. (NYSE:DHR – Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,739 shares of the conglomerate’s stock after purchasing an additional 52 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Danaher were worth $399,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC raised its stake in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after acquiring an additional 3,217,631 shares during the period. Bank of New York Mellon Corp raised its position in shares of Danaher by 5.4% in the fourth quarter. Bank of New York Mellon Corp now owns 8,589,019 shares of the conglomerate’s stock valued at $1,971,609,000 after purchasing an additional 441,012 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Danaher by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in Danaher by 0.6% in the 4th quarter. Fisher Asset Management LLC now owns 4,578,945 shares of the conglomerate’s stock worth $1,051,097,000 after buying an additional 26,305 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Danaher by 3.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,066,755 shares of the conglomerate’s stock valued at $933,524,000 after buying an additional 135,047 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Insider Buying and Selling
In other news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.10% of the stock is owned by insiders.
Analysts Set New Price Targets
Check Out Our Latest Report on Danaher
Danaher Price Performance
DHR opened at $205.02 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a 1 year low of $196.80 and a 1 year high of $281.70. The stock’s 50 day simple moving average is $222.02 and its 200 day simple moving average is $242.18. The firm has a market cap of $146.53 billion, a price-to-earnings ratio of 38.83, a PEG ratio of 2.66 and a beta of 0.82.
Danaher (NYSE:DHR – Get Free Report) last issued its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting the consensus estimate of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same period in the prior year, the business earned $2.09 EPS. As a group, analysts predict that Danaher Co. will post 7.63 earnings per share for the current year.
Danaher Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date of this dividend is Friday, March 28th. Danaher’s dividend payout ratio is currently 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- Where Do I Find 52-Week Highs and Lows?
- How to Protect Your Portfolio When Inflation Is Rising
- What is Insider Trading? What You Can Learn from Insider Trading
- 3 Tech Stocks Defying Sector Weakness and Thriving in 2025
- What Are the U.K. Market Holidays? How to Invest and Trade
- Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.